Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Aandeel NYXOAH BRU:NYXH.BL, BE0974358906

Laatste koers (eur) Verschil Volume
8,040   +0,140   (+1,77%) Dagrange 7,700 - 8,100 13.937   Gem. (3M) 14,1K

Forum Nyxoah geopend

165 Posts
Pagina: «« 1 ... 4 5 6 7 8 9 »» | Laatste | Omlaag ↓
  1. Havik 12 april 2024 12:45
    Dr. Boon joins Nyxoah from the Thomas Jefferson University, where he will continue part time as a professor and Vice Chairman, Education. He is dual board-certified in otolaryngology – head and neck surgery, as well as sleep medicine. Dr. Boon is one of two sleep surgeons with Jefferson Health to pioneer the use of hypoglossal nerve stimulation therapy (HGNS) and is internationally recognized as one of the most experienced surgeons performing HGNS procedures. He has lectured worldwide on obstructive sleep apnea, has numerous publications and is co-editor of the first book on HGNS.

    Hiermee krijgen ze weer meer voet aan wal in de VS.
  2. forum rang 10 voda 30 mei 2024 14:46
    Kepler Cheuvreux herhaalt het koopadvies voor NYXOAH
    donderdag 30 mei 2024 - 12:22u -

    Kepler Cheuvreux verlaagt het koersdoel van NYXOAH naar € 16,50 van € 19,20. Het koopadvies van woensdag 20 maart 2024 wordt herhaald. Dit vorige advies heeft geresulteerd in een rendement van -48,86%.

    www.guruwatch.nl/advies/171137/NYXOAH...
  3. forum rang 10 voda 18 juni 2024 16:17
    Degroof Petercam herhaalt het koopadvies voor NYXOAH
    dinsdag 18 juni 2024 - 11:38u -

    Degroof Petercam verlaagt het koersdoel van NYXOAH naar € 19,00 van € 21,00. Het koopadvies van woensdag 20 maart 2024 wordt herhaald. Dit vorige advies heeft geresulteerd in een rendement van -50,76%.

    www.guruwatch.nl/advies/171552/NYXOAH...
  4. forum rang 6 Nakennis 25 juni 2024 12:29
    finance.yahoo.com/news/5-10-7-afforda...

    Nyxoah (NASDAQ:NYXH) is a company commercializing treatment devices for sleep apnea. That makes the stock an interesting one to watch as sleep apnea has become a major health threat. Sleep apnea is proven to be associated with major health risks, creating a strong market opportunity.

    Nyxoah’s hypoglossal neurostimulation therapy treats moderate to severe obstructive sleep apnea. The company’s May 14 earnings report suggests that the company may receive FDA approval for the device as early as the end of 2024. That said, Nyxoah has already commercialized outside of the United States. Furthermore, the company is currently experiencing rapid sales growth with revenues having increased by nearly 200% in the first quarter.

    Losses are currently very stable, and the company shouldn’t need to raise further capital until sometime in 2025. If the company is correct and receives FDA approval by the end of 2024, expect share prices to jump upward quickly as the U.S. market opens to it.
165 Posts
Pagina: «« 1 ... 4 5 6 7 8 9 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.